Hochhaus, A
Saglio, G
Hughes, T P
Larson, R A
Kim, D-W
Issaragrisil, S
le Coutre, P D
Etienne, G
Dorlhiac-Llacer, P E
Clark, R E
Flinn, I W
Nakamae, H
Donohue, B
Deng, W
Dalal, D
Menssen, H D
Kantarjian, H M
Article History
Received: 2 November 2015
Revised: 6 January 2016
Accepted: 18 January 2016
First Online: 3 February 2016
Competing interests
: Authors declare the following relationships with pharmaceutical companies: Novartis—receipt of honoraria (AH, GS, TPH, DWK, PdlC, GE, REC, HN), research funding (all authors), nonfinancial support (GE, HN), employment (BD, WD, DD, HDM) and stock ownership (BD, DD, HDM); Pfizer—receipt of honoraria (AH, RAL, PdlC, GE, REC) and research funding (AH, DWK, REC); Ariad—receipt of honoraria (AH, TPH, GS, PdlC, GE) and research funding (AH, TPH); Bristol-Myers Squibb—receipt of honoraria (AH, GS, TPH, DWK, PdlC), research funding (AH, TPH, REC, IWF) and nonfinancial support (GE); Sanofi—receipt of honoraria (REC) and research funding (REC); Ilyang—receipt of honoraria (DWK).